Скачать или смотреть Tolerability of CAR-T therapies in clinical trials and in the real-world

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, compares the toxicity of different chimeric antigen receptor T-cell (CAR-T) products in pivotal clinical trials and in the real-world setting. Overall, data from the real-world shows that CAR-T products are less toxic than in clinical trials. Dr Subklewe explains that the management of CAR-T-related side effects in clinical practice is improving, and data is suggesting that the inclusion criteria from pivotal trials is not entirely relevant in the real-world. Lastly, Dr Subklewe comments on the different toxicity profiles of available CAR-T therapies, highlighting the importance of determining which product is the most appropriate for each patient. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.